ClinicalTrials.gg
Status unknownNCT03475719Updated Mar 23, 2018

A Clinical Trial to Evaluate the Safety and Pharmacokinetic

A Phase 1 interventional study of HUG186-B and HUG186-D and HUG186 in Osteoporosis, Postmenopausal, sponsored by Huons Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-23.

Sponsored by Huons Co., Ltd. (part of Huons Global) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Osteoporosis, Postmenopausal with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Osteoporosis, Postmenopausal · Korea, Republic of.

Started
2018
with 1 other
Phase 1
Only one
of the 12
Registered
9th of 12
by date
Lead sponsor
1 of 12
Huons Co., Ltd.

Among the 12 studies in Osteoporosis, Postmenopausal with a site in Korea, Republic of, this one is one of 2 that started in 2018, is the only one in phase 1, and was the 9th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 12 studies in Osteoporosis, Postmenopausal with a site in Korea, Republic of is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Osteoporosis, Postmenopausal with a site in Korea, Republic of as a file.
02

Study summary

A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men, age≥19 years of age, women are eligible. Postmenopausal is defined as any of the following:

    • Amenorrhea for 12 or more months
    • FSH and estradiol in the postmenopausal range per local normal range.
  2. Body weight of ≥ 55 kg, 18.5 to 30.0
  3. No morbid symptom or sign, based on physical examination, with no innate or chronic disease.
  4. Subject that is considered appropriate for participating in the study by an investigator, based on clinical laboratory test (hematology, clinical chemistry, urinalysis) that is performed according to the characteristics of drugs.
  5. Subject that agree to apply sun cream in case of daylight exposure for more than 1hours
  6. Subjects must be able to listen to and understand the detailed statement of , and willing to decide to participate in the study, follow the study directions and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. A disease or history in hepatobiliary system, kidney, digestive system, respiratory system, hemato-oncological system, endocrine system, neuro-psychiatric system, musculo-skeletal system, immune system, otorhinolaryngological system or cardiovascular system.
  2. A history of to drugs and its additives or clinically significant hypersensitivity to any other drug.
  3. History of drug abuse, or positive in drug screening test.
  4. Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.
  5. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of investigational drug, and this will affect this study or the safety of the subjects at discretion of study investigator.
  6. Participation in another clinical trial or a bioequivalent study within 3 months prior to the first administration of investigational drug (The finish time of previous study is the day of the last administration of study drug)
  7. Whole blood donation within 2 months or component donation within 1 month, prior to the first administration of investigational drug, or transfusion within 1 month prior to the first administration of investigational drug.
  8. Prolonged excessive alcohol consumption (>21 units/week, 1 unit=10g of pure alcohol), or subjects who can not abstain from drinking from 24 hours prior to hospitalization until the discharge.
  9. Smoking more than 10 cigarettes per day, excessive caffeine consumption (example: instant coffee > 5 cups/day)
  10. Subjects who are judged to be inappropriate for this study by investigators according to other reasons including clinical lab test result
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    HUG186-B and HUG186-D

    Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)

    Drug: HUG186-B and HUG186-D

  • Experimental
    HUG186

    Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)

    Drug: HUG186

Interventions

  • DrugHUG186-B and HUG186-D

    Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)

  • DrugHUG186

    Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)

06

What researchers measure

Primary outcomes

  1. AUC0-t of Bazedoxifene

    Area under the curve(AUCt) of Bazedoxifene

    Time frame: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)

  2. Cmax of Bazedoxifene

    Maximum observed concentration(Cmax) of Bazedoxifene

    Time frame: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)

  3. AUC0-t of Cholecalciferol

    Area under the curve(AUCt) of Cholecalciferol

    Time frame: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)

  4. Cmax of Cholecalciferol

    Maximum observed concentration(Cmax) of Cholecalciferol

    Time frame: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)

Secondary outcomes

  1. Tmax of Bazedoxifene

    Tmax of Bazedoxifene

    Time frame: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)

  2. AUCinf of Bazedoxifene

    AUCinf of Bazedoxifene

    Time frame: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)

  3. t1/2 of Bazedoxifene

    t1/2 of Bazedoxifene

    Time frame: 0, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120h(17points)

  4. Tmax of Cholecalciferol

    Tmax of Cholecalciferol

    Time frame: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)

  5. AUCinf of Cholecalciferol

    AUCinf of Cholecalciferol

    Time frame: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)

  6. t1/2 of Cholecalciferol

    t1/2 of Cholecalciferol

    Time frame: -24, -12, -6, 0, 2, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96h(18points)

07

Study locations

1 site
  • Huons
    Gyeonggi-do, Seongnam-si 13486, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Feb 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2018
First posted
Mar 23, 2018
StartActual
Jan 11, 2018
Primary completionActual
Feb 11, 2018
CompletionEst.
Apr 30, 2018
Last update
Mar 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03475719
Lead sponsor
Huons Co., Ltd.
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
Jan 11, 2018
Primary completion
Feb 11, 2018
Completion
Apr 30, 2018 (estimated)
Last update
Mar 23, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion